The patent filing announced today highlight’s the multiple product opportunities that are ahead for OptiBiotix’s Lactobacillus plantarum cholesterol reducing strain.
Having demonstrated efficacy as a single agent in a human study, the strain has the potential to replace or supplement alternatives that can cause undesirable side effects, as well as with ingredients where there is the potential to enhance the overall reduction of risk of Cardiovascular disease.
From a Pharma angle a combination with statins (often the subject of controversy) could help to reduce statin dosage.
Other ingredients which may act synergistically include Betaclucans (found in oats), Plant Sterols (Such as Benecol and Flora ProActiv) and essential fatty oils such as Omega 6 and 3. Optibiotix’s products. The human study also showed a reduction in hypertension (abnormally high blood pressure) meaning that the product, particularly in combination with other ingredients, could mount a multi-pronged attack on heart disease. Commercial discussions will continue with potential partners across both consumer and pharma to fully exploit the opportunity.
